Letter to the Editor: Comment on "fGF21 response to critical illness: Effect of blood glucose control and relation with cellular stress and survival" by Thiessen S.E., et al

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 10, 2015, Pages L102-L103

  Plomgaard, Peter ^a   Weigert, Cora ^b  

^a Rigshospitalet   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FIBROBLAST GROWTH FACTOR 21; GLUCAGON; GLUCAGON RECEPTOR; INSULIN; MESSENGER RNA; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE MONITORING; CELL STRESS; CELL SURVIVAL; CRITICAL ILLNESS; DIET RESTRICTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXERCISE; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETTER; LIVER CELL; LIVER LEVEL; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RODENT; UPREGULATION; ANIMAL; BLOOD; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; MALE; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; CRITICAL ILLNESS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERGLYCEMIA; MALE; OXIDATIVE STRESS;

EID: 84943802792     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3193     Document Type: Letter

References (10)

1. Thiessen SE, Vanhorebeek I, Derese I, Gunst J, Van den Berghe G. FGF21 response to critical illness: effect of blood glucose control and relation with cellular stress and survival. J Clin Endocrinol Metab. 2015;10.1210/jc.2015-2700.
2. Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab. 2009;94(9):3594-3601.
3. Mai K, Andres J, Biedasek K, et al. Free fatty acids link metabolism and regulation of the insulinsensitizing fibroblast growth factor21. Diabetes. 2009;58(7):1532-1538.
4. Arafat AM, Kaczmarek P, Skrzypski M, et al. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: A novel mechanism of glucagonstimulated lipolysis? Diabetologia. 2013;56(3):588-597.
5. Berglund ED, Kang L, LeeYoung RS, et al. Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARalpha and FGF21 transcripts in vivo. Am J Physiol Endocrinol Metab. 2010;299(4):E607-E614.
6. Tong X, Muchnik M, Chen Z, et al. Transcriptional repressor E4-binding protein 4 (E4BP4) regulates metabolic hormone fibroblast growth factor 21 (FGF21) during circadian cycles and feeding. J Biol Chem. 2010;285(47):36401-36409.
7. Chavez AO, MolinaCarrion M, AbdulGhani MA, Folli F, DeFronzo RA, Tripathy D. Circulating fibroblast growth factor21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32(8):1542-1546.
8. Jung WJ, Park BH, Chung KS, et al. Glucagon levels, disease severity, and outcome in severe sepsis. Shock. 2015;43(6):563-568.
9. Roth E, Funovics J, Mühlbacher F, et al. Metabolic disorders in severe abdominal sepsis: glutamine deficiency in skeletal muscle. Clin Nutr. 1982;1(1):25-41.
10. Wolfe RR, Durkot MJ, Allsop JR, Burke JF. Glucose metabolism in severely burned patients. Metabolism. 1979;28(10):1031-1039.